EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Triple Negative Breast Cancer

뉴스 본문을 불러오고 있어요.

EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Triple Negative Breast Cancer | 웨이프 WAPE

EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of Adult Patients With Unresectable Or Metastatic Triple Negative Breast Cancer

기사 요약

관련 종목

댓글 —